Related Experiment Video
Updated: Feb 24, 2026
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Potential-Resolved Electrochemiluminescence for Simultaneous Determination of Triple Latent Tuberculosis Infection
Bin Zhou1, Mingyao Zhu1, Yan Hao1
1Department of Chemistry, Jinan University , Guangzhou 510632, PR China.
Insights
A novel immunosensor simultaneously detects three latent tuberculosis infection (LTBI) markers: interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2. This advancement offers a sensitive and reliable method for LTBI diagnosis.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Immunosensing
Background:
- Latent tuberculosis infection (LTBI) diagnosis requires sensitive detection of multiple biomarkers.
- Existing methods for LTBI marker detection often lack multiplexing capabilities or sufficient sensitivity.
Purpose of the Study:
- To develop a novel electrochemiluminescence (ECL) immunosensor for simultaneous detection of three key LTBI markers.
- To enhance sensitivity and reliability in diagnosing LTBI through a multiplexed approach.
Main Methods:
- Fabrication of potential-resolved ECL nanoprobes using gold nanoparticles, magnetic beads, carbon quantum dots, and CdS quantum dots.
- Immobilization of specific antibodies for interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2 on a patterned indium tin oxide electrode.
- Simultaneous detection of LTBI markers via antibody-functionalized ECL nanoprobes and potential-resolved ECL signals.
Main Results:
- The developed immunosensor achieved simultaneous determination of IFN-γ, TNF-α, and IL-2 with high sensitivity.
- Detection ranges for the LTBI markers were established as 1.6-200 pg mL⁻¹.
- The ECL intensities directly correlated with the concentrations of the detected biomarkers.
Conclusions:
- The novel multiplexed ECL immunosensor provides an effective platform for simultaneous LTBI marker detection in human serum.
- This approach facilitates more accurate and reliable clinical diagnosis of latent tuberculosis infection.
- The potential-resolved strategy offers a significant advancement in sensitive and simultaneous biomarker analysis.
Abstract:
A novel electrochemiluminescence (ECL) immunosensor based on the potential-resolved strategy was first developed for simultaneous determination of triple latent tuberculosis infection (LTBI) markers with high sensitivity, interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin (IL)-2. In this work, luminol and self-prepared carbon quantum dots and CdS quantum dots were integrated onto gold nanoparticles and magnetic beads in sequence to fabricate potential-resolved ECL nanoprobes with signal amplification. IFN-γ-antibody (Ab)1, TNF-α-Ab1, and IL-2-Ab1 were separately immobilized on three spatially resolved areas of a patterned indium tin oxide electrode to capture the corresponding LTBI markers, which were further recognized by IFN-γ-Ab2, TNF-α-Ab2, and IL-2-Ab2-functionalized ECL nanoprobes. The binding reaction of antibody-functionalized ECL nanoprobes and the captured LTBI markers will generate three sensitive and potential-resolved ECL signals during one potential scanning, and the ECL intensities reflect the concentrations of IFN-γ, TNF-α, and IL-2 in the range of 1.6-200 pg mL-1. Therefore, the multiplexed ECL immunosensor provided an effective approach for simultaneous detection of triple LTBI markers in human serum, so it will be beneficial to facilitate more accurate and reliable clinical diagnosis for LTBI.
